DD258011A5 - Verfahren zur herstellung substituierter n hoch 7-amidinomitomycin-c-derivate - Google Patents
Verfahren zur herstellung substituierter n hoch 7-amidinomitomycin-c-derivate Download PDFInfo
- Publication number
- DD258011A5 DD258011A5 DD86289675A DD28967586A DD258011A5 DD 258011 A5 DD258011 A5 DD 258011A5 DD 86289675 A DD86289675 A DD 86289675A DD 28967586 A DD28967586 A DD 28967586A DD 258011 A5 DD258011 A5 DD 258011A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- mitomycin
- item
- reaction
- substituted
- amino
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims abstract description 65
- 229960004857 mitomycin Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000003512 tertiary amines Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 19
- -1 alkoxy radical Chemical class 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 125000001424 substituent group Chemical class 0.000 claims description 5
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims description 2
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 claims description 2
- UNBDDZDKBWPHAX-UHFFFAOYSA-N n,n-di(propan-2-yl)formamide Chemical compound CC(C)N(C=O)C(C)C UNBDDZDKBWPHAX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- JYMQQKIMCZOSMX-UHFFFAOYSA-N thiomorpholine-4-carbaldehyde Chemical compound O=CN1CCSCC1 JYMQQKIMCZOSMX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- QMRIWYCCTCNABA-UHFFFAOYSA-N indole-4,7-quinone Chemical compound O=C1C=CC(=O)C2=C1C=CN2 QMRIWYCCTCNABA-UHFFFAOYSA-N 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 abstract description 4
- 229950004406 porfiromycin Drugs 0.000 abstract description 4
- 239000002798 polar solvent Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 8
- 229930192392 Mitomycin Natural products 0.000 description 5
- HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 5
- HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/728,650 US4652644A (en) | 1985-04-29 | 1985-04-29 | Process for preparation of N7 -amidino substituted mitomycin C derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD258011A5 true DD258011A5 (de) | 1988-07-06 |
Family
ID=24927725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD86289675A DD258011A5 (de) | 1985-04-29 | 1986-04-28 | Verfahren zur herstellung substituierter n hoch 7-amidinomitomycin-c-derivate |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4652644A (it) |
| KR (1) | KR910002080B1 (it) |
| CN (1) | CN1020731C (it) |
| AR (1) | AR242210A1 (it) |
| AT (1) | AT394724B (it) |
| CA (1) | CA1247617A (it) |
| CS (1) | CS271331B2 (it) |
| DD (1) | DD258011A5 (it) |
| DK (1) | DK168708B1 (it) |
| ES (1) | ES8706685A1 (it) |
| FI (1) | FI83519C (it) |
| GR (1) | GR861152B (it) |
| HU (1) | HU194243B (it) |
| IT (1) | IT1208605B (it) |
| LU (1) | LU86411A1 (it) |
| NO (1) | NO164543C (it) |
| OA (1) | OA08243A (it) |
| PT (1) | PT82471B (it) |
| SU (1) | SU1436881A3 (it) |
| YU (1) | YU45778B (it) |
| ZW (1) | ZW5386A1 (it) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354380A (ja) * | 1986-08-26 | 1988-03-08 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体 |
| JPH0867676A (ja) * | 1994-03-30 | 1996-03-12 | Eisai Kagaku Kk | 保護アミノチアゾリル酢酸誘導体 |
| JP3202960B2 (ja) * | 1998-02-17 | 2001-08-27 | 大塚化学株式会社 | ハロゲン化剤及び水酸基のハロゲン化方法 |
| CN104710426B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 苯并吡咯里西啶生物碱及其制备方法和用途 |
| CN104478885B (zh) * | 2014-12-12 | 2017-08-01 | 常州大学 | 9‑氨基‑9a‑烯丙基苯并吡咯里西啶生物碱的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1135270B (it) * | 1980-04-12 | 1986-08-20 | Erba Farmitalia | 3-amidino-ansamicine |
| US4487769A (en) * | 1982-06-04 | 1984-12-11 | Bristol-Myers Company | Amidines |
| US4567256A (en) * | 1983-05-09 | 1986-01-28 | Bristol-Myers Company | Amidine process |
-
1985
- 1985-04-29 US US06/728,650 patent/US4652644A/en not_active Expired - Fee Related
-
1986
- 1986-02-11 CA CA000501609A patent/CA1247617A/en not_active Expired
- 1986-02-28 KR KR1019860001449A patent/KR910002080B1/ko not_active IP Right Cessation
- 1986-03-04 ZW ZW53/86A patent/ZW5386A1/xx unknown
- 1986-03-13 AR AR86303372A patent/AR242210A1/es active
- 1986-03-13 CN CN86101611A patent/CN1020731C/zh not_active Expired - Fee Related
- 1986-04-17 AT AT0101886A patent/AT394724B/de not_active IP Right Cessation
- 1986-04-24 FI FI861720A patent/FI83519C/fi not_active IP Right Cessation
- 1986-04-25 OA OA58844A patent/OA08243A/xx unknown
- 1986-04-28 IT IT8620228A patent/IT1208605B/it active
- 1986-04-28 SU SU864027308A patent/SU1436881A3/ru active
- 1986-04-28 DK DK193786A patent/DK168708B1/da not_active IP Right Cessation
- 1986-04-28 ES ES554469A patent/ES8706685A1/es not_active Expired
- 1986-04-28 DD DD86289675A patent/DD258011A5/de not_active IP Right Cessation
- 1986-04-28 LU LU86411A patent/LU86411A1/fr unknown
- 1986-04-28 PT PT82471A patent/PT82471B/pt not_active IP Right Cessation
- 1986-04-28 NO NO861652A patent/NO164543C/no unknown
- 1986-04-29 CS CS863117A patent/CS271331B2/cs unknown
- 1986-04-29 GR GR861152A patent/GR861152B/el unknown
- 1986-04-29 HU HU861783A patent/HU194243B/hu not_active IP Right Cessation
- 1986-04-29 YU YU70086A patent/YU45778B/sh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI83519C (fi) | 1991-07-25 |
| GR861152B (en) | 1986-09-02 |
| CN86101611A (zh) | 1986-12-17 |
| LU86411A1 (fr) | 1986-11-05 |
| CS311786A2 (en) | 1989-12-13 |
| YU45778B (sh) | 1992-07-20 |
| PT82471B (pt) | 1988-10-14 |
| NO164543C (no) | 1990-10-17 |
| NO164543B (no) | 1990-07-09 |
| HUT40665A (en) | 1987-01-28 |
| CS271331B2 (en) | 1990-09-12 |
| CA1247617A (en) | 1988-12-28 |
| ES8706685A1 (es) | 1987-07-01 |
| CN1020731C (zh) | 1993-05-19 |
| DK168708B1 (da) | 1994-05-24 |
| AT394724B (de) | 1992-06-10 |
| FI861720A (fi) | 1986-10-30 |
| NO861652L (no) | 1986-10-30 |
| IT8620228A0 (it) | 1986-04-28 |
| DK193786A (da) | 1986-10-30 |
| ATA101886A (de) | 1991-11-15 |
| KR860008201A (ko) | 1986-11-12 |
| OA08243A (fr) | 1987-10-30 |
| FI861720A0 (fi) | 1986-04-24 |
| DK193786D0 (da) | 1986-04-28 |
| FI83519B (fi) | 1991-04-15 |
| ES554469A0 (es) | 1987-07-01 |
| SU1436881A3 (ru) | 1988-11-07 |
| ZW5386A1 (en) | 1986-10-01 |
| US4652644A (en) | 1987-03-24 |
| HU194243B (en) | 1988-01-28 |
| IT1208605B (it) | 1989-07-10 |
| PT82471A (en) | 1986-05-01 |
| KR910002080B1 (ko) | 1991-04-03 |
| AR242210A1 (es) | 1993-03-31 |
| YU70086A (en) | 1987-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0287907A1 (de) | Pyrazolo[3,4-d]pyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel | |
| DE3319992C2 (it) | ||
| DE3413489C2 (it) | ||
| DD289529A5 (de) | Verfahren zur herstellung heterozyklischer verbindungen | |
| EP0645390A1 (de) | Trisubstituierte Pyrimido/5,4-d/-pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
| DD258011A5 (de) | Verfahren zur herstellung substituierter n hoch 7-amidinomitomycin-c-derivate | |
| DE3447003C2 (de) | 7-Acylamino-9a-methoxymitosane, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE3217769A1 (de) | Mitomycon-analoge verbindungen | |
| AT394723B (de) | Verfahren zur herstellung von neuen substituierten 7-oxomitosanen | |
| CH666036A5 (de) | In 6-stellung substituierte mitomycin-analoge. | |
| EP0331093A1 (de) | Neue Benzimidazo[1,2-c] chinazoline, ihre Herstellung und Verwendung | |
| DE3933881C2 (de) | 2-Carbonyl-substituierte N,N'-Di(trimethoxybenzoyl)piperazine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Zusammensetzungen | |
| AT336605B (de) | Verfahren zur herstellung von neuen triazolopyridazinen und ihren salzen | |
| DD216013A5 (de) | Verfahren zur herstellung neuer ethendiamin- und guanidin-derivate | |
| CH633291A5 (de) | Verfahren zur herstellung von pyrimido(1,2-a)benzimidazolderivaten. | |
| DE2901537C2 (it) | ||
| AT397091B (de) | Verfahren zur herstellung von neuen mitosan-derivaten | |
| CH590278A5 (it) | ||
| DE2448257A1 (de) | Cumarinabkoemmlinge, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| DE2459630A1 (de) | Verfahren zur herstellung von pyrimidinoaminomethylergolinderivaten | |
| DE2855853A1 (de) | Benzamidderivate, verfahren zu ihrer herstellung sowie ihre verwendung | |
| AT322562B (de) | Verfahren zur herstellung von neuen pyridopyridazinderivaten und deren pharmazeutisch vertraeglichen salzen | |
| AT399339B (de) | Verfahren zur herstellung von teilweise neuen substituierten 7-oxomitosanen | |
| AT397092B (de) | Verfahren zur herstellung von neuen mitosan-derivaten | |
| DD261158A1 (de) | Verfahren zur herstellung von 2-aminoalkyl-3,4-dihydro-4-oxo-7h-pyrrolo 2.3-d pyrimidinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |